Search results
‘I looked like The Elephant Man’: Life with extreme swelling disease HAE
The Telegraph via Yahoo News· 7 days agoMy first attack was at the age of four, although I don’t remember it. One morning, I couldn’t get my...
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
Motley Fool via Yahoo Finance· 13 hours agoNearly all of BioCryst's revenue comprises sales of Orladeyo, which treats the swelling disorder ...
BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
GuruFocus.com via Yahoo Finance· 23 hours agoThe company's flagship product, ORLADEYO (berotralstat), is an oral treatment designed for the...
Ruconest dosage: Form, strength, how to use, and more
Healthline· 6 days agoRuconest (C1 esterase inhibitor, recombinant) is a prescription drug that’s used to treat sudden swelling in people with hereditary angioedema. Ruconest ...
Cost and Berinert: Financial Assistance Options, Savings, More
Healthline· 6 days agoBerinert (C1 esterase inhibitor [human]) is a prescription drug used to treat hereditary angioedema (HAE) attacks in adults and children. Berinert’s cost ...
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year - KalVista Pharma...
Benzinga· 6 days agoKALV, today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company's investigational novel, oral plasma kallikrein inhibitor for the on-demand ...
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
InvestorPlace· 5 days agoPay close attention to gene editing stocks. All in an effort to help treat sickle-cell anemia,...
Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
CNBC· 7 days agoThe outlook is starting to look bright for biotech stocks, according to some. With markets now...
Pharming Group (PHAR) Scheduled to Post Quarterly Earnings on Wednesday
ETF DAILY NEWS· 1 day agoPharming Group (NASDAQ:PHAR – Get Free Report) is scheduled to announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Analysts
ETF DAILY NEWS· 2 days agoShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings ...